MA25411A1 - Microorganismes attenues pour le traitement d'infection. - Google Patents

Microorganismes attenues pour le traitement d'infection.

Info

Publication number
MA25411A1
MA25411A1 MA26404A MA26404A MA25411A1 MA 25411 A1 MA25411 A1 MA 25411A1 MA 26404 A MA26404 A MA 26404A MA 26404 A MA26404 A MA 26404A MA 25411 A1 MA25411 A1 MA 25411A1
Authority
MA
Morocco
Prior art keywords
infection
treatment
attenuated microorganisms
attenuated
microorganisms
Prior art date
Application number
MA26404A
Other languages
English (en)
Inventor
Gordon Dougan
David William Holden
Jacqueline Elizabeth Shea
Zoe Hindle
Joseph David Santangelo
Original Assignee
Microscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microscience Ltd filed Critical Microscience Ltd
Publication of MA25411A1 publication Critical patent/MA25411A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA26404A 1999-05-10 2001-11-09 Microorganismes attenues pour le traitement d'infection. MA25411A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9910812.8A GB9910812D0 (en) 1999-05-10 1999-05-10 Vaccine composition

Publications (1)

Publication Number Publication Date
MA25411A1 true MA25411A1 (fr) 2002-04-01

Family

ID=10853168

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26404A MA25411A1 (fr) 1999-05-10 2001-11-09 Microorganismes attenues pour le traitement d'infection.

Country Status (28)

Country Link
US (3) US6756042B1 (fr)
EP (2) EP1183269B1 (fr)
JP (1) JP4583607B2 (fr)
KR (2) KR100680391B1 (fr)
CN (1) CN1177863C (fr)
AP (1) AP1470A (fr)
AT (2) ATE346090T1 (fr)
AU (1) AU763898B2 (fr)
BR (1) BRPI0010418B8 (fr)
CA (1) CA2372553C (fr)
CY (1) CY1107656T1 (fr)
CZ (1) CZ301926B6 (fr)
DE (2) DE60031974T2 (fr)
DK (1) DK1183269T3 (fr)
EA (1) EA004921B1 (fr)
ES (1) ES2277591T3 (fr)
GB (1) GB9910812D0 (fr)
HU (1) HUP0201117A3 (fr)
IL (3) IL146255A0 (fr)
MA (1) MA25411A1 (fr)
MX (1) MXPA01011477A (fr)
NO (1) NO329520B1 (fr)
NZ (1) NZ539260A (fr)
OA (1) OA11940A (fr)
PT (1) PT1183269E (fr)
TR (1) TR200702949T2 (fr)
WO (1) WO2000068261A2 (fr)
ZA (1) ZA200108912B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG119177A1 (en) * 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
ATE403728T1 (de) * 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20110027321A1 (en) * 2007-05-25 2011-02-03 Emergent Product Development Gaithersburg Inc. Chlamydia Vaccine Comprising HtrA Polypeptides
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
CA2733425A1 (fr) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccins contre clostridium difficile, et procedes d'utilisation
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
EP3552621A3 (fr) 2013-10-11 2020-01-08 Servizo Galego De Saúde (Sergas) Vaccins vivants atténués
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3922255A1 (fr) 2020-06-10 2021-12-15 Prokarium Limited Thérapie du cancer
EP4124342A1 (fr) 2021-07-28 2023-02-01 Prokarium Limited Thérapie du cancer avec bacteries vivantes attenuees
CA3238816A1 (fr) 2021-12-09 2023-06-15 Prokarium Limited Polytherapie anticancereuse
WO2024061748A1 (fr) 2022-09-21 2024-03-28 Prokarium Limited Souche de salmonelle avec plateforme d'atterrissage intégrée au niveau chromosomique
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
AU2509592A (en) 1991-08-22 1993-03-16 Washington University Polynucleotide probes for salmonella
AU2778992A (en) 1991-10-07 1993-05-03 Idaho Research Foundation Inc., The Genetic construct for selection of homologous recombinants on a single selective medium
AU3130893A (en) 1991-11-15 1993-06-15 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
US5356797A (en) 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
EP0668779A4 (fr) 1992-11-06 1996-08-21 Univ Minnesota COMPOSITION PROTEGEANT DE L'INFECTION PAR LA PASTEURELLOSE A -i(P. MULTOCIDA).
WO1994026933A1 (fr) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Empreinte genetique: mutagenese d'insertion et selection genetique
WO1996011708A1 (fr) 1994-10-18 1996-04-25 Board Of Regents, The University Of Texas System Expression membranaire de genes heterologues
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
US5700928A (en) 1995-10-16 1997-12-23 Smithkline Beecham, P.L.C. Polynucleotide encoding saliva binding protein
AU7738396A (en) 1995-11-14 1997-06-05 General Hospital Corporation, The Salmonella secreted proteins and uses thereof
US6030624A (en) 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP1017283B1 (fr) 1997-02-14 2004-12-15 Merck & Co., Inc. Formules de vaccins a base de polynucleotides
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
ATE403728T1 (de) 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
CN1196787C (zh) 1998-11-09 2005-04-13 微科学有限公司 毒力基因和蛋白质及其用途
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2001032697A2 (fr) 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Genes et proteines virulents ainsi que leur utilisation
JP3414342B2 (ja) * 1999-11-25 2003-06-09 日本電気株式会社 集積回路チップの実装構造および実装方法
US6951732B2 (en) 1999-12-23 2005-10-04 Vmax Ltd. Virulence genes, proteins, and their use
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
ATE457998T1 (de) 2010-03-15
CA2372553A1 (fr) 2000-11-16
HUP0201117A2 (en) 2002-08-28
NO20015464D0 (no) 2001-11-08
PL354355A1 (en) 2004-01-12
DE60043868D1 (de) 2010-04-01
NZ539260A (en) 2007-01-26
BRPI0010418B8 (pt) 2021-05-25
DE60031974T2 (de) 2007-03-15
GB9910812D0 (en) 1999-07-07
IL186993A (en) 2010-02-17
US7887816B2 (en) 2011-02-15
ATE346090T1 (de) 2006-12-15
JP4583607B2 (ja) 2010-11-17
JP2003509008A (ja) 2003-03-11
CN1177863C (zh) 2004-12-01
CN1360594A (zh) 2002-07-24
KR100680391B1 (ko) 2007-02-08
BR0010418B1 (pt) 2013-04-16
IL146255A (en) 2008-11-26
EP1183269A1 (fr) 2002-03-06
CZ301926B6 (cs) 2010-08-04
BR0010418A (pt) 2003-07-22
US20040191866A1 (en) 2004-09-30
AP2001002317A0 (en) 2001-12-31
TR200702949T2 (tr) 2007-08-21
CA2372553C (fr) 2011-09-27
CZ20014030A3 (cs) 2002-06-12
EA004921B1 (ru) 2004-10-28
HUP0201117A3 (en) 2004-01-28
EP1702927B1 (fr) 2010-02-17
WO2000068261A3 (fr) 2001-02-08
NO20015464L (no) 2001-11-08
KR100811319B1 (ko) 2008-03-07
AU763898B2 (en) 2003-07-31
US7211264B2 (en) 2007-05-01
WO2000068261A2 (fr) 2000-11-16
US6756042B1 (en) 2004-06-29
OA11940A (en) 2006-04-12
EP1702927A1 (fr) 2006-09-20
KR20020018193A (ko) 2002-03-07
DE60031974D1 (de) 2007-01-04
CY1107656T1 (el) 2013-04-18
DK1183269T3 (da) 2007-04-02
MXPA01011477A (es) 2002-06-04
KR20060101563A (ko) 2006-09-25
AU4593200A (en) 2000-11-21
PT1183269E (pt) 2007-02-28
ES2277591T3 (es) 2007-07-16
NO329520B1 (no) 2010-11-01
EA200101187A1 (ru) 2002-04-25
IL146255A0 (en) 2002-07-25
ZA200108912B (en) 2002-12-24
US20080274139A1 (en) 2008-11-06
AP1470A (en) 2005-09-26
EP1183269B1 (fr) 2006-11-22

Similar Documents

Publication Publication Date Title
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
MA25823A1 (fr) Compositions pour le traitement de l'eau.
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
MA26822A1 (fr) Composes pour le traitement d'une ischemie.
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR2785521B1 (fr) Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires
MA26207A1 (fr) Compositions de traitement de l'eau.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
NO20022949D0 (no) Attenuerte mikroorganismer for behandling av infeksjon
FR2795398B1 (fr) Procede et installation pour le traitement d'effluents agricoles
FR2800728B1 (fr) Procede de traitement bacterien d'effluents contenant au moins un ether par gordona terrae cip i-2194
FR2787783B1 (fr) Procede de traitement bacterien d'effluents contenant au moins un ether
FR2818150B1 (fr) Composition pour le traitement d'objets destines a etre desinfectes
FR2759290B1 (fr) Minalcipran pour le traitement de l'incontinence urinaire
FR2705574B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocéphalie.
FR2712076B1 (fr) Séchoir pour produits humides, notamment de boues de station d'épuration.
FR2804331B1 (fr) Valve pour le traitement de l'hydrocephalie